Genzyme | search
Click here to view Genzyme news from 60+ newspapers.
Bookmark or Share- Sanofi Oncology | Working to Improve the Lives of People with CancerSanofi is advancing potentially transformative therapies to help improve the lives of people living with cancer. We strive to be a partner of choice in our core areas: Our ambition is to develop both backbone therapies and potential first-in-class medicines for difficult-to-treat cancer types. Whether it’s pursuing scientific discoveries ...
- Genzyme - WikipediaGenzyme focuses on six areas of medicine relating to lysosomal storage diseases, renal disease, orthopedics, transplant and immune diseases, oncology, genetics and diagnostics. The first orphan-drug for Genzyme that FDA approved was Ceredase , a drug for treating Gaucher disease .
- Sanofi Pharmaceuticals - Healthcare Innovations | Sanofi USAHealth Equity Starts with Listening. We know that for people to live their healthiest lives possible, there must be an ecosystem that provides a continuum of care. Sanofi’s CSR and DEI teams have prioritized engaging communities across the country in listening sessions in order to provide resources that address the specific needs of each ...
- Eleven years after buying Genzyme, Sanofi officially ditches ... - STATEleven years after Sanofi bought Genzyme for about $20.1 billion, the parent company said Thursday it will no longer call its specialty care unit Sanofi Genzyme ― just Sanofi, as part of a ...
- FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an ... - SanofiApproval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile. Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells.
More
